Welcome to our dedicated page for Sutro Biopharma news (Ticker: STRO), a resource for investors and traders seeking the latest updates and insights on Sutro Biopharma stock.
Sutro Biopharma develops next-generation antibody-drug conjugates for oncology through a cell-free protein engineering platform. Recurring company news covers single- and dual-payload ADC design, pipeline programs such as STRO-004, STRO-006 and STRO-227, and preclinical data across tissue factor, ITGB6 and PTK7-targeting programs.
Updates also address clinical and regulatory disclosures, research and development collaborations, operating results, financing activity, equity compensation matters, investor and scientific conference participation, and Nasdaq listing compliance. The coverage reflects Sutro’s focus on site-specific ADCs for solid tumors and other cancer indications with limited treatment options.
Sutro Biopharma (NASDAQ: STRO) announced the promotions of Carlos Lugo to Vice President of Quality and CMC Regulatory Operations, and Devendra Luhar to Vice President of Manufacturing & Plant Operations. Lugo brings over 25 years of experience, having previously held leadership roles at Bayer and Merck, while Luhar has more than 30 years in biotech operations with experience at companies like Novartis. These changes reflect Sutro's commitment to advancing its oncology therapeutics and enhancing its cGMP manufacturing capabilities.
Sutro Biopharma (NASDAQ: STRO) will present at the 2020 Wedbush PacGrow Healthcare Virtual Conference on August 11, 2020, at 11:30 a.m. EDT. CEO Bill Newell will lead the presentation, which can be accessed via the company’s Investor Relations page. Sutro focuses on oncology therapeutics utilizing advanced protein engineering. Notable candidates include STRO-001 and STRO-002, both in Phase 1 trials for multiple myeloma and ovarian/endometrial cancers, respectively. Sutro's innovative platforms, XpressCF® and XpressCF+™, support its mission to enhance cancer treatment.
Sutro Biopharma (NASDAQ: STRO) reported Q2 2020 financial results, revealing revenue of $9.5 million, down from $10.5 million in Q2 2019. Operating expenses increased to $25.9 million from $24.2 million. Despite challenges, progress continues with clinical trials for STRO-001 and STRO-002, both in Phase 1. Notably, STRO-002 shows promising anti-tumor activity in ovarian cancer patients. The company also recorded a $29.9 million net income, primarily from unrealized gains related to Vaxcyte common stock holdings.
Sutro Biopharma (NASDAQ: STRO) presented new preclinical data for STRO-002, a folate receptor alpha-targeting antibody-drug conjugate, at the 2020 AACR Virtual Annual Meeting II. The data showed STRO-002's potential to induce immunogenic cell death in FolRα positive tumor cells and enhance anti-tumor responses when combined with PD-L1 blockade. Sutro plans to initiate clinical trials for STRO-002 in combination with PD-1/PD-L1 agents in 2021, indicating a promising direction for cancer therapeutics.